WallStreetZen

NASDAQ: AZN
Astrazeneca Plc Earnings & Revenue

AZN past earnings growth

How has AZN's earnings growth performed historically?
Company
75.61%
Industry
21.22%
Market
104.53%
AZN's earnings have grown slower (10.48% per year) than the US Drug Manufacturers - General industry average (16.9%)
Performance
AZN's earnings have grown slower (10.48% per year) than the US market average (31.1%)
Performance
AZN's earnings growth is accelerating - its growth over the last year (75.61%) is above its 5-year compound annual rate (10.48%)
Performance

AZN past revenue growth

How has AZN's revenue growth performed historically?
Company
14.9%
Industry
18.29%
Market
41.42%
AZN's revenue has grown slower (4.18% per year) than the US Drug Manufacturers - General industry average (5.42%)
Performance
AZN's revenue has grown slower (4.18% per year) than the US market average (19.51%)
Performance
AZN's revenue growth is accelerating - its growth over the last year (14.9%) is above its 5-year compound annual rate (4.18%)
Performance

AZN earnings and revenue history

Current Revenue
$29.5B
Current Earnings
$3.8B
Current Profit Margin
12.8%
AZN's has not demonstrated consistent long-term earnings growth over the past 10 years (-50.68%)
Performance

AZN Return on equity

Current Company
26%
Current Industry
33.2%
Current Market
23.1%
AZN's Return on Equity (26%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

AZN Return on assets

Current Company
5.6%
Current Industry
7.3%
AZN is generating lower Return on Assets (5.6%) than the US Drug Manufacturers - General industry average (7.55%)
Performance

AZN Return on capital employed

Current Company
11.02%
Current Industry
11.7%
AZN has gotten more efficient at generating Return on Capital (11.02%) compared to 3 years ago (7.65%)
Performance

Astrazeneca Earnings & Revenue FAQ

What were AZN's earnings last quarter?

Astrazeneca (NASDAQ: AZN) reported Q2 2021 earnings per share (EPS) of $0.21, up 27.59% year over year. Total Astrazeneca earnings for the quarter were $550.00 million. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $0.29.

What was AZN's earnings growth in the past year?

As of Q4 2021, Astrazeneca's earnings has grown 75.61% year over year. This is 54.39 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 21.22%. Astrazeneca's earnings in the past year totalled $3.77 billion.

What was AZN's revenue last quarter?

Astrazeneca (NASDAQ: AZN) reported Q2 2021 revenue of $8.22 billion up 31% year over year. In the same quarter last year, Astrazeneca's revenue was $6.28 billion.

What was AZN's revenue growth in the past year?

As of Q4 2021, Astrazeneca's revenue has grown 14.9% year over year. This is 3.39 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 18.29%. Astrazeneca's revenue in the past year totalled $29.53 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.